IDH3A and chondrosarcoma: Isocitrate dehydrogenase inhibitors have shown promising efficacy in preclinical and early clinical trials, although data specific to chondrosarcoma remains limited.[24] Additionally, the hedgehog signaling pathway, which plays a role in chondrosarcoma progression, is being targeted with inhibitors, though clinical results have been mixed.[24] Immunotherapy is another emerging field in the treatment of advanced chondrosarcoma.